Chronic rhinosinusitis in primary antibody immunodeficient patients

Bernatowska, Ewa; Mikołuć, Bożena; Krzeski, Antoni; Piątosa, Barbara; Gromek, I.

doi:10.1016/j.ijporl.2006.04.013

Cited by 16 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This disorder includes selective IgA deficiency (SIgAD), common variable immunodeficiency (CVID), and specific antibody deficiency (SAD), which is characterized by normal IgG levels but an impaired response to polysaccharide vaccines [17][18][19][20][21]. One study reported considerable differences in the incidence of sinusitis in PIDs, such as agammaglobulinemia (11.52%), CVID (9.4%), SAD (1.8%), IgG subclass deficiency (13.41%), SIgAD (6.58%), and hyper-IgM syndrome (0.7%) [19]. The manifestation of recurrent sinusitis in patients with immune dysregulation (especially PAD patients) demonstrates the importance of immunological testing in patients with recurrent sinusitis [22].…”

Section: Sinusitismentioning

confidence: 99%

Infectious and Noninfectious Pulmonary Complications in Patients With Primary Immunodeficiency Disorders

Yazdani

Abolhassani

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Primary immunodeficiency disorders (PIDs) are caused by 1 or more defects of the immune system. Patients are more likely to experience recurrent and/or severe infections and tend to develop a wide range of complications. Respiratory diseases are the main and initial manifestation in most cases and the most common complication. Pulmonary complications cause significant morbidity and mortality in patients with PIDs. Early diagnosis and appropriate treatment can prevent or at least slow the development of respiratory complications. Since the spectrum of pulmonary complications in PIDs is broad, we divided pulmonary complications into upper respiratory complications (eg, sinusitis, otitis media, and laryngeal angioedema) and lower respiratory complications (eg, pneumonia, bronchitis, bronchiectasis, interstitial lung diseases, organizing pneumonia, pulmonary adenopathies and malignancies, hyperreactive airway diseases, pulmonary dysgenesis, and adverse reactions to treatment). This review covers the main respiratory manifestations in patients with PIDs. Key words: Primary immunodeficiency disorders. Pulmonary complications. Upper respiratory tract. Lower respiratory tract. ResumenLas inmunodeficiencias primarias (PIDs) son enfermedades causadas por uno o más defectos del sistema inmunológico. Estos pacientes presentan con frecuencia infecciones recidivantes y/o severas así como otro tipo de complicaciones. Las patologías respiratorias son la principal y más frecuente manifestación y complicación de las PIDs. Las complicaciones de estas patologías pulmonares constituyen una de las principales causas de morbimortalidad entre los pacientes que sufren PIDs. El diagnóstico temprano y el tratamiento adecuado pueden prevenir, o al menos retrasar, la aparición de las complicaciones respiratorias en estos pacientes. Dado que el espectro de las enfermedades pulmonares es muy amplio, hemos dividido estas complicaciones entre aquellas que afectan a las vías aéreas superiores (sinusitis, otitis media y angioedema laríngeo, etc.) y las que afectan a las vías aéreas bajas (neumonía, bronquitis, bronquiectasias, enfermedades pulmonares intersticiales, neumonía organizada, adenopatías pulmonares y neoplasias, hiperreactividad bronquial, disgenesia pulmonar y las debidas a los efectos secundarios del tratamiento instaurado). Este artículo revisa las manifestaciones respiratorias que se observan más frecuentemente en los pacientes con PIDs. Palabras clave: Inmunodeficiencias primarias. Complicaciones pulmonares. Vías respiratorias altas. Vías respiratorias bajas.

show abstract

Section: Sinusitismentioning

confidence: 99%

Infectious and Noninfectious Pulmonary Complications in Patients With Primary Immunodeficiency Disorders

Yazdani

Abolhassani

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

“…22,29,30 In children with severe immunodeficiency disorders such as common variable immunodeficiency (CVID), high-dose (500-600 mg/kg) IVIG has demonstrated better outcomes than lower doses (150 mg/kg). 12 Long-term complications may persist, however, despite IVIG replacement. 31 Although some have expressed concern for increased intraoperative risks given a narrower ethmoid cavity in children, ESS has been shown to be safe and effective in the pediatric population.…”

Section: Resultsmentioning

confidence: 99%

“…2,4,22,29,34 A number of selective immunoglobulin deficiencies, specifically IgG3 subclass, IgA, and IgM deficiencies, have been consistently identified in this group of patients. 6,7,12,16,18,24,35 Preimmunization antipneumococcal titers have also been examined and found to be decreased as well, particularly in patients with the more severe forms of immunodeficiency such as CVID. 3,15,31 The studies in this literature review demonstrate the significance of primary immunodeficiency in the development of chronic sinus disease, with a range of 10% to 54% of those with recalcitrant CRS found to have primary immune dysfunction.…”

Section: Discussionmentioning

confidence: 99%

“…5,6 Appropriate evaluation for primary immunodeficiency may include quantitative serum immunoglobulins and specific antibody responses. [7][8][9][10]12,[18][19][20][21][22] The purpose of this review was to systematically examine the existing evidence for the association of primary immunodeficiency disorders and CRS that is unresponsive to standard therapies, typically consisting of topical and systemic steroids, antibiotics, and endoscopic sinus surgery. It is important to identify these patients, as immunoglobulin replacement therapy may provide symptom relief and prevent serious long-term pulmonary complications.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Primary immunodeficiency and recalcitrant chronic sinusitis: a systematic review

Mazza

Lin

2016

Int Forum Allergy Rhinol.

View full text Add to dashboard Cite

Patients with recalcitrant CRS should be evaluated for primary immunodeficiency. This should include as assessment of quantitative serum immunoglobulin levels as well as functional antibody responses. Medical therapy, particularly immunoglobulin replacement therapy, appears to be most effective when administered at high doses early in the disease course. The addition of surgery is less clearly supported, but may also provide benefit if performed early.

show abstract

“…Todo ello es consistente con los resultados de otros estudios en los que, además, se documenta una mejoría en la calidad de vida de los pacientes con inmunodeficiencias primarias que reciben tratamiento sustitutivo con IgG intravenosa. [30][31][32][33][34][35][36][37] En México existe una población creciente de pacientes con inmunodeficiencias primarias cuya supervivencia es cada vez mayor debido a los avances en el tratamiento; sin embargo, no contamos con estudios que describan la calidad de vida de estos pacientes.…”

Section: Discussionunclassified

Calidad de vida de los pacientes con inmunodeficiencias primarias de anticuerpos

et al. 2016

View full text Add to dashboard Cite

INTRODUCCIÓNLas inmunodeficiencias primarias son enfermedades hereditarias generalmente causadas por alteraciones monogénicas. Pueden afectar el sistema inmunitario en su desarrollo, su función, o en ambos.1 Se clasifican de acuerdo con la afección particular del sistema inmuno- ABSTRACTPrimary immunodeficiencies (PID) are genetic diseases affecting immunological normal response. In the great majority of cases affected individual sare predisposed to recurrent and / or severe infections with impaired quality of life (QoL). The most frequent PID are defects in the production of antibodies. When diagnosis and treatment are not done properly, permanent damage may occur in affected organs and further affecting QoL.Objective: To evaluate QoL in patients with antibody PID compared with QoL of healthy controls. Methods:Cross-sectional study with the application of the instrument "Pediatric Quality of Life Inventory" (PedsQL) in its Mexican Spanish validated version. The PedsQL score difference between children with PID and healthy children was determined by the Student t test. The effect of a delayed in diagnosis was evaluated by analysis in a covariance model. 28 patients were included. The median age was 5 years and 5 months.

show abstract

Chronic rhinosinusitis in primary antibody immunodeficient patients

Cited by 16 publications

References 15 publications

Infectious and Noninfectious Pulmonary Complications in Patients With Primary Immunodeficiency Disorders

Infectious and Noninfectious Pulmonary Complications in Patients With Primary Immunodeficiency Disorders

Primary immunodeficiency and recalcitrant chronic sinusitis: a systematic review

Calidad de vida de los pacientes con inmunodeficiencias primarias de anticuerpos

Contact Info

Product

Resources

About